GlassScriptPhysician profile
Carl Ankrah
NPI 1699935502
$6,967.78
in general payments reported to CMS, 2019-2025
24 companies · $2,320 in 2025
The $2,320 reported for 2025 was more than what 94% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $971 · 2022: $843 · 2023: $1,058 · 2024: $1,775 · 2025: $2,320.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,078 · Education: $75.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,077.84 |
| Education | $75.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,048.33 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $1,048.55 | 2021-2025 | Invega Sustenna, Spravato |
| Otsuka America Pharmaceutical, INC. | $675.30 | 2021-2025 | Abilify Asimtufii, Abilify Maintena, Rexulti |
| Neurocrine Biosciences, INC. | $444.23 | 2021-2025 | Ingrezza |
| Alkermes, INC. | $426.35 | 2021-2025 | Aristada, Lybalvi |
| E.R. Squibb & Sons, L.L.C. | $403.04 | 2024-2025 | Cobenfy |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $367.47 | 2021-2024 | Rexulti |
| Lundbeck LLC | $199.76 | 2021-2025 | Abilify Maintena, Rexulti |
| Teva Pharmaceuticals USA, INC. | $191.54 | 2025 | Uzedy |
| Ironshore Pharmaceuticals INC. | $175.92 | 2023-2024 | Jornay Pm |
| Genzyme Corporation | $128.42 | 2022 | |
| Novo Nordisk INC | $125.00 | 2022 | |
| Viatris Specialty LLC | $121.96 | 2025 | Yupelri |
| Adlon Therapeutics L.P. | $119.92 | 2021 | |
| Coloplast Corp | $106.96 | 2024 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $100.00 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $98.62 | 2025 | Caplyta |
| Axsome Therapeutics, INC. | $49.49 | 2025 | Auvelity |
| Collegium Pharmaceutical, INC. | $47.23 | 2025 | Jornay Pm |
| Corium, LLC | $24.87 | 2022 | |
| Luye Pharma (USA) LTD. | $18.74 | 2025 | Erzofri Extended-Release |
| Orexo US, INC. | $16.26 | 2022 | |
| Tris Pharma INC | $14.93 | 2021 | |
| Indivior INC. | $14.89 | 2023 | Perseris |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carl Ankrah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.